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Limitations of antipsychotic medications 
in schizophrenia
o this day, the pharmacological management of
schizophrenia is based upon the serendipitous discovery,
over 50 years ago, of the antipsychotic effects of chlor-
promazine.
1 Subsequent drug discovery for schizophre-
nia treatments was directed at identifying agents with
comparable properties inferred by quite indirect criteria
such as protection against apomorphine-induced canine
vomiting or improvement in the conditioned avoidance
response, while at the same time seeking increased
potency and attenuated neurologic side effects.
2 Carlson
3
proposed that antipsychotic drugs produced their ther-
apeutic effects by blocking dopamine receptors.
Advances in ligand-binding techniques led Snyder and
Seemen to demonstrate that there was a specific and
highly robust correlation between the clinical potencies
of antipsychotics and their ability to block the dopamine
D2 receptor.
4,5 With the target of therapeutic action
clearly identified, pharmacologists could then “build”
into new agents other neurotransmitter receptor inter-
actions to minimize side effects. However, these modifi-
cations, while virtually eliminating extrapyramidal side
effects, introduced other serious problems including
weight gain, hyperlipidosis, and glucose intolerance.
6
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All current drugs approved to treat schizophrenia appear
to exert their antipsychotic effects through blocking the
dopamine D2 receptor. Recent meta-analyses and com-
parative efficacy studies indicate marginal differences in
efficacy of newer atypical antipsychotics and the older
drugs, and little effects on negative and cognitive symp-
toms. This review integrates findings from postmortem,
imaging, and drug-challenge studies to elucidate a cor-
ticolimbic “pathologic circuit” in schizophrenia that may
be particularly relevant to the negative symptoms and
cognitive impairments of schizophrenia. Potential sites
for pharmacologic intervention targeting glutatatergic,
GABAergic, and cholinergic neurotransmission to treat
these symptoms of schizophrenia are discussed.  
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ciated with the progressive decline in the number of
patients held in state mental hospitals. The vast majority
of these suffered from psychotic disorders, and the infer-
ence was that the antipsychotic medications had a pro-
found impact on their care, permitting this deinstitu-
tionalization. A less sanguine view would note that
currently half of the homeless suffer from serious men-
tal illness,
7 and that the number of prison beds on a per-
capita basis has largely replaced the closed mental hos-
pital beds, consistent with a shift in the locus of
confinement.
8 So, in spite of the semblance of substan-
tial improvements in treatment of schizophrenia and
related psychotic disorders, schizophrenia, which affects
approximately 1% of the population, remains the sev-
enth most costly medical illness to society, and is still
associated with a life-long disability for the vast major-
ity of patients suffering from the disease.
9
Results of recent clinical studies further raise concern
over the modest advances that have been achieved over
the last five decades in developing more effective drugs
for treating schizophrenia. While meta-analyses com-
paring the first-generation antipsychotics to the second-
generation antipsychotics do suggest some modest supe-
riority of the second-generation antipsychotics, these
effects are limited to positive symptoms known to be
sensitive to D2 receptor antagonism.
10 In the large-scale
CATIE (Clinical Antipsychotic Trials of Intervention
Effectiveness) trial, Lieberman et al
11 compared several
second-generation antipsychotics with a first-generation
antipsychotic, perphenazine. The majority of patients in
each group discontinued their antipsychotics owing to
inefficacy or intolerable side effects. When clozapine was
compared with other second-generation antipsychotics,
it did exhibit modest but significant superiority over
these other drugs. A separate study carried out in
England, Cost Utility of the Latest Antipsychotic Drugs
and Schizophrenia Study (CUtLASS 1), also found few
differences in effectiveness between first-generation
antipsychotics and second-generation antipsychotics in
non-refractory patients.
12As pointed out by Lieberman,
13
both the CATIE and the CUtLASS studies are “effec-
tiveness” studies, which examine the therapeutic
response in real-world clinical situations. This design is
markedly different from the randomized clinical trial of
“efficacy,” in which a new drug is compared with placebo
in a very select group of patients subject to a myriad of
exclusionary criteria. Thus, basing a drug discovery effort
for schizophrenia on the assumption that it is primarily
a disorder of dopaminergic dysfunction has led to the
introduction of antipsychotics that are marginally more
efficacious than their “progenitors,” chlorpromazine and
haloperidol. 
Starting about 20 years ago, psychopharmacologists
began to focus on other components of schizophrenia
rather than just the antipsychotic responsive positive
symptoms (ie, hallucinations, delusion, and thought dis-
order). Negative symptoms including apathy, poverty of
thought, anhedonia, lack of drive, disorganization, and
social isolation were observed to covary independently
of positive symptoms, be much more enduring, and cor-
relate inversely with outcome.
14,15With advances in neu-
ropsychology, much more rigorous testing delineated
the specific impairments in memory, problem-solving,
and executive functions, which were noted a century
ago with the designation of “dementia praecox.”
16,17 At
the same time, progress in both structural and func-
tional brain imaging revealed substantial cortical
involvement in schizophrenia. On average, cortical vol-
ume is reduced and lateral ventricular volume is
increased in individuals with a first episode of schizo-
phrenia, and these differences increase over the next 5
to 10 years.
18,19 Functional imaging studies demonstrate
impairments in the ability to perform tasks that engage
the prefrontal cortex or the hippocampus, which corre-
sponds with their inability to activate these areas.
20
Diffusion tensor imaging (DTI) has shown abnormali-
ties in white-matter tracts of frontotemporal, fron-
toparietal, and temporooccipital connections,
21,22 pro-
viding further evidence for the presence of structural
disconnectivity in schizophrenia. Finally, event-related
potentials reveal disruption in cortical processing of
sensory stimuli regardless of modality.
22 Thus, the pre-
ponderance of evidence supports the notion that schiz-
ophrenia is a progressive disorder that diffusely affects
the corticolimbic system.
Pharmacological aspects
360
Selected abbreviations and acronyms
DAAO D-amino acid oxidase
DMXBA 3-(2,4 dimethoxy) benzylidene-anabaseine
GABA -aminobutyric acid
GMS glycine modulatory site
NAC N-acetylcysteine
nAChR nicotinic acetylcholine receptor
NMDA N-methyl-D-aspartate
PAM positive allosteric modulator
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and schizophrenia
Dissociative anesthetics such as ketamine and phency-
clidine (PCP) have been known since their introduction
a half-century ago to produce in adults a syndrome dif-
ficult to distinguish from schizophrenia.
23,24While these
drugs have complex interactions in the nervous system,
Javitt and Zukin
25 noted that the psychotomimetic
effects of PCP occurred at plasma concentrations that
cause a noncompetitive, use-dependent antagonism of
N-methyl-D-aspartate (NMDA) receptors.
26 Ketamine
infused in normal volunteers at doses that do not cause
delirium/dementia produced the full range of signs and
symptoms of schizophrenia, with positive symptoms,
negative symptoms, and the selective cognitive
deficits.
27,28 Subsequent studies showed that low-dose ket-
amine caused in normal volunteers the physiologic
abnormalities associated with schizophrenia, including
abnormal event-related potentials,
29 eye-tracking abnor-
malities
30 and enhanced subcortical dopamine release.
31
Individuals with stabilized schizophrenia exhibited
marked sensitivity to ketamine with recurrence of indi-
vidual specific symptoms.
32
With a greater availability of brain tissue for histologic
and neurochemical analyses, a number of findings have
crystallized over the last 15 years as they have been con-
firmed in different laboratories using a variety of tech-
niques including quantitative neurochemistry, immuno-
cytochemistry, in situ hybridization, and DNA chip
arrays. One of the first neurochemical abnormalities
described in postmortem studies in schizophrenia was a
reduction in the cortical activity of glutamate decar-
boxylase (GAD), the enzyme that synthesizes γ-amino
butyric acid (GABA), in the cortex.
33 More recent stud-
ies have revealed a much more selective effect primar-
ily on the parvalbumin (PV
+)-expressing, fast-firing
GABAergic interneurons in the intermediate layers of
the cortex and in subsectors of the hippocampus that
provide recurrent inhibition to the pyramidal cells.
34,35
Thus, the reduction in the expression of GAD67, PV, and
the GABA transporter has been demonstrated in this
neuronal population.
36That the downregulation of these
presynaptic markers reflects reduced activity of these
GABAergic neurons is inferred by the compensatory
upregulation of postsynaptic GABAA receptors and its
α2-containing subunit.
37Another recurrent finding from
Golgi-stain studies and more recent immunocytochem-
istry of spinophilin, a protein enriched in dendritic
spines, is the reduction in dendritic complexity and spine
density on pyramidal neurons in several cortical regions,
consistent with the overall cortical atrophy in schizo-
phrenia.
38,39
These core pathologic features of schizophrenia have
been linked to NMDA receptor hypofunction. Several
studies have demonstrated that subacute treatment of
rats with dissociative anesthetics results in a downregu-
lation of GAD67 and PV expression in the GABAergic
neurons in the intermediate layers of the cortex and a
consequent disinhibition of pyramidal neuronal firing.
40,41
This disinhibition of the pyramidal neurons is consistent
with the results of functional imaging studies in the hip-
pocampus, as well as the elevated evoked subcortical
dopamine release in normal individuals challenged with
ketamine.
31The paradoxically reduced firing of the PV
+-
GABAergic interneurons may be secondary to the
decreased flux of calcium through their NMDA recep-
tors, which causes a misperception of reduced excitatory
drive.
42 NMDA receptors also play an important role in
dendritic elaboration and spine development.
43 Mice that
are homozygotes for a null mutation of serine racemase,
the enzyme that synthesizes D-serine, exhibit marked
reduction in NMDA receptor function.
44 Cortical pyra-
midal neurons of these serine racemase knockout mice
have significantly reduced dendritic complexity and
spine density, as compared with their wild-type litter-
mates, with the pathology quite similar to that observed
in schizophrenia.
45
Schizophrenia is a disorder with a high degree of heri-
tability, and recent genetic studies have provided sup-
port for a role for NMDA receptors in this disorder.
Most of the evidence is derived from association studies,
although that strategy has come under criticism by advo-
cates of “unbiased” genome-wide association study
(GWAS) strategy. Meta-analysis has strongly implicated
the gene encoding D-amino acid oxidase (DAAO),
which regulates the availability of D-serine, as well as
G72, a gene encoding a protein that binds to and inhibits
DAAO (for review, see ref 42). Meta-analysis has also
pointed to NR2B, a component of the NMDA receptor,
as a risk gene for schizophrenia.
46 Other risk genes
include neuregulin 1, which among other actions directly
modulates NMDA receptor activity,
47 and dysbindin,
which is concentrated in glutamatergic terminals.
48
Integrating the postmortem, genetic, and animal modeling
results has suggested a plausible pathologic circuit in schiz-
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receptors on the fast-firing PV
+-GABAergic interneurons
in the intermediate layers of the cortex results in down-
regulation of GAD67 and PV expression, reduced
inhibitory postsynaptic potentials (IPSPs), and disinhibi-
tion of the postsynaptic pyramidal cells.
42 NMDA receptor
hypofunction can be due to elevated endogenous inhibitors
such as kynurenic acid or N–acetyl aspartyl glutamate
(NAAG), reduced availability of the endogenous co-ago-
nist D-serine, or heritable abnormalities in NR2B expres-
sion or function. Electrophysiological correlates include
loss of gamma-band responses to sensory stimuli and ele-
vated neuronal activity in the default mode.
49 Disinhibition
of glutamatergic output from the ventral hippocampus
would drive the firing of dopaminergic neurons in the ven-
tral tegmental area and enhanced subcortical dopamine
release, which in PET studies correlates with psychosis.
50
Thus, in this model, psychosis is a downstream event. 
Hypofunction of NMDA receptors could account for
other aspects of the disorder. First, given the role of
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Figure 1. Schematic representation of the synaptic circuitry relevant to the pathophysiology of schizophrenia. NMDA receptor hypofunction can be pro-
duced by exogenous antagonists such as ketamine, endogenous antagonists such as N-acetyl aspartyl glutamate (NAAG) or kyneurenic acid,
reduced availability of D-serine due to increased activity of D-amino acid oxidase (DAAO) or mutant NR2B. This results in dendritic dysplasia on
pyramidal neurons and reduced activity of the parvalbumin positive GABAergic interneurons. Reduced recurrent inhibition disrupts cortical pro-
cessing, causing cognitive impairment and negative symptoms and increased excitatory drive to the ventral tegmental area (VTA), leading to psy-
chosis. An allelic variant of the gene encoding the α7 nicotinic receptor causes reduced expression and disrupts sensory gating. NMDA, N-methyl-
D-aspartate; GABA, γ-aminobutyric acid; DA, dopamine; NBM, nucleus basalis of Meynert; nAchR, nicotinic acetylcholine receptor; Glu, glutamate
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51 it could
account for the finding of abnormal distribution of cor-
tical GABAergic interneurons in some cases.
52 Secondly,
persistent hypofunction of NMDA receptors is consis-
tent with the reduced pyramidal neuron dendritic com-
plexity, reduced spine density, and net compaction of the
neuropil in schizophrenia.
37
Obviously, the pathophysiology of schizophrenia is much
more complex and nuanced than suggested by this sim-
plified model. Indeed, a number of putative risk genes
encode transcriptional factors that affect brain develop-
ment.
53 Other risk genes encode products involved in
myelination.
54 Furthermore, in recognition of the varia-
tion in symptoms among patients who satisfy the diag-
nostic criteria for schizophrenia and its complex genet-
ics, where literally hundreds of genes of modest effect
might be involved, the proposed “pathologic circuit” rep-
resents at best a crude first approximation of the patho-
physiology of schizophrenia. Nevertheless, it does yield
a host of potential targets for therapeutic intervention,
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Figure 2. Potential pharmacologic interventions to treat schizophrenia: (i) Enhance NMDA receptor function by increasing synaptic glycine concentrations
with an inhibitor of GlyT1, administering exogenous D-serine, inhibiting D-amino acid oxidase or by treating with an mGluR5 agonist that aug-
ments NMDA receptor function; (ii) Increase the excitability of the parvalbumin-positive GABAergic interneurons with a α7nicotine receptor-
positive modulator; (iii) Reduce pyramidal neuron excitability with GABAA receptor-positive modulator. (iv) Decrease disinhibited pyramidal neu-
ron glutamate release with an mGluR2/3 agonist. NMDA, N-methyl-D-aspartate; GABA, γ-aminobutyric acid; DA, dopamine; NBM, nucleus basalis
of  Meynert; mAchR, metabotrophic acetylcholine receptor; Glu, glutamate; DAAO, D-amino acid oxidase
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maceutical industry. It is these potential therapeutic tar-
gets related to this circuit that are the subject of this
review (Figure 2). Of particular interest is the fact that
these targets would intervene in the primary cortical
pathology of schizophrenia and thus potentially treat the
negative symptoms and cognitive deficits.
Targeting the glutamatergic synapse
Structure and function of the NMDA receptor
The NMDA receptor, with its triple gate for activation, is
a critical postsynaptic mediator of activity-dependent
synaptic plasticity. Throughout most of the brain, the het-
erotetrameric receptor is composed of two NR1 subunits
and two NR2 subunits, all of which contribute trans-
membrane domains to the pore of the ion channel. The
NR1 subunit has eight different splice variants, which
may affect channel function differently by associating
with different intracellular signaling pathways.
55 NR2 sub-
units may be expressed in four different forms (NR2A-
D), and in some regions of the nervous system may be
substituted by two different forms of NR3 subunits, each
of which confer different biophysical and pharmacologic
properties to the channel.
56 Mg
2+ occludes the ion chan-
nel at resting membrane potential. Hence, opening of the
“voltage gate” by expelling Mg
2+ with depolarization of
the postsynaptic cell is one requirement for conductance
through the channel. A second requirement is opening of
the “ligand gate” by agonist binding at glutamate bind-
ing sites on the NR2 subunits. A third requirement is ago-
nist binding at glycine modulatory sites (GMS, also the
Glycine B receptor) on the NR1 channel-encoding sub-
unit.
57 Endogenous polyamines also modulate NMDA
receptors by potentiating the action of glutamate.
58
Dissociative anesthetics gain access to and bind within
the NMDA receptor channel pore when the channel is
open, and as such are both noncompetitive and use-
dependent antagonists.
59,60
The key roles that the NMDA receptor is known to play
in neurodevelopment and in activity-dependent plastic-
ity make it all the more plausible as a contributor to the
pathophysiology of schizophrenia, particularly deficits
in cognitive function. Because it opens only when the
postsynaptic neuron receives several simultaneous exci-
tatory inputs to sufficiently depolarize it so as to relieve
the Mg
2+ blockade, the NMDA receptor functions as a
molecular coincidence detector. The NMDA receptor ion
channel is characterized by high Ca
2+ permeability, and
the influx of Ca
2+ triggers a cascade of intracellular
events that mediate local, acute synaptic plasticity as well
as changes in gene expression that influence long-term
neural plasticity and have trophic effects.
61,62Whether or
not symptoms of schizophrenia are caused in part by
hypofunctional signaling through NMDA receptor-
mediated pathways, enhancing NMDA receptor-medi-
ated activity may improve cognition and neural plastic-
ity, thereby reducing the debilitating negative and
cognitive symptoms. On the other hand, a significant risk
in pursuing NMDA receptor activation as a therapeutic
pathway is that of excitotoxic damage to the brain, which
can result from excessive activation of NMDA recep-
tors.
63With this caveat in mind, efforts to treat symptoms
of schizophrenia through the NMDA receptor have
focused on positive modulation of the receptor rather
than increasing agonist binding at the glutamate site.
The glycine modulatory site
The GMS of the NMDA receptor is a potentially rich tar-
get for therapeutics. Despite the presence of endogenous
high potency agonists glycine and D-serine,
64,65 the GMS
is not saturated in vivo,
66,67 supporting the idea that
administration of GMS agonists could benefit patients by
enhancing activation of NMDA receptors. Furthermore,
evidence of reduced cerebrospinal fluid (CSF) and serum
D-serine levels in schizophrenic patients
68,69 as well as evi-
dence of elevated levels of the endogenous GMS antag-
onist kynurenate in postmortem brain and CSF
70,71 sug-
gest that the GMS occupancy is downshifted or shifted
toward antagonism in the disease state. 
There have been more than 80 clinical trials of agents
that increase agonist occupancy of the GMS in schizo-
phrenia, including D-serine, glycine, D-cycloserine, D-
alanine, and sarcosine. Several of these studies have
reported significant improvements over multiple symp-
tom domains while others have not. Aside from intrinsic
differences in efficacy between candidate GMS regula-
tors, methodological factors likely contribute to the vari-
ability in results among these trials, most notably small
sample sizes, variability in concomitant typical and atyp-
ical antipsychotic use, and subject compliance. Also,
important to consider from the point of view of evalu-
ating the promise of the GMS strategy, the majority of
these trials have been conducted using glycine and/or
Pharmacological aspects
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most potent agonist of the site. Studies employing cloned
NMDA receptors expressed in a Xenopus oocyte system
suggest the potency of D-serine is about three times that
of glycine,
72 and D-cycloserine is a partial agonist with
only about half the efficacy of glycine at the GMS.
73 Still,
glycine and D-cycloserine have been more widely tested
than D-serine due to historical approval of these agents
for human use, glycine as a nonessential amino acid, and
D-cycloserine as a second-line antibiotic effective
against Mycobacterium tuberculosis.
A recent meta-analysis of strategies to enhance NMDA
receptor-mediated neurotransmission in schizophrenia
reported the striking finding that NMDA-enhancing
molecules as a whole exerted statistically significant
effects on total psychopathology, depressive symptoms,
negative symptoms, cognitive symptoms, positive symp-
toms, and general psychopathology in descending order
of effect size.
74 The meta-analysis included results from
26 double-blind, placebo-controlled clinical trials in
which the treatment lasted at least 4 weeks. Agents
tested were glycine, D-cycloserine, D-serine, sarcosine,
and D-alanine. Pooling of data from different studies
was made possible by including only those for which
enough data were available to calculate a standardized
metric of the degree of improvement seen in a particu-
lar symptom domain relative to placebo, or the effect
size (ES). There was some heterogeneity in the trials that
were included, in that patients enrolled were adminis-
tered concomitant typical or atypical antipsychotics and
in others were not. Also, trials of chronic stable and
acutely exacerbated schizophrenia were included. When
the effects of different molecules were assessed sepa-
rately, glycine was found to have significant effects on
total psychopathology, positive symptoms, and depres-
sive symptoms. D-serine was found effective on total
psychopathology, negative symptoms, and cognitive
symptoms. Sarcosine, an endogenous inhibitor of the
glycine transporter, was effective on total psy-
chopathology, negative symptoms, and general psy-
chopathology. D-cylcoserine was not effective on any
domain of schizophrenia symptoms. However, if the tri-
als that use clozapine as the antipsychotic are excluded,
the duration of exposure restricted and compliance con-
trolled the data suggest that D-cycloserine significantly
reduces negative symptoms.
63
The findings of the meta-analysis by Tsai and Lin
74 pro-
vide some interesting new illumination for the results of
the largest individual study to date of glycine and D-
cycloserine, a multicenter trial called the Cognitive and
Negative Symptoms in Schizophrenia Trial (CONSIST).
The CONSIST study found no statistically significant
effects of either glycine or D-cyloserine on negative
symptoms or cognitive performance in patients with
chronic schizophrenia. Previous smaller studies of high
doses of glycine administered concurrently with typical
and atypical antipsychotics had reported improvements
negative and cognitive symptoms.
75-77 High doses were
purported to be required to achieve sufficiently high
serum glycine levels for clinical efficacy, and difficulty
with compliance was noted. The CONSIST study did
report a significant effect of site (P<0.01), as well as
lower serum levels of glycine than was achieved in pre-
vious studies. Thus, one of the concerns raised about the
interpretation of this study with respect to its results with
glycine was that variability in patient compliance
between inpatient and outpatient clinics could account
for the negative result. Indeed, restricting the results to
those obtained with inpatients, for whom compliance
was not in question, both glycine and D-cycloserine sig-
nificantly (P<0.03) reduced negative symptoms.
However, the results of the meta-analysis, which includes
the CONSIST study, showed that when double-blind,
placebo-controlled trials with glycine were considered
together, glycine still had no significant effect on nega-
tive symptoms, but rather was effective on positive and
depressive symptoms, which were not assessed by the
CONSIST. Nonetheless, as serum levels of glycine were
not part of the meta-analysis, the lack of any significant
dose-response with glycine on negative symptoms, pos-
itive symptoms, or total psychopathology is still open to
the question of whether compliance is a major issue in
evaluating outcomes. Despite the negative findings of
glycine efficacy with respect to negative and cognitive
symptoms, the issues of compliance and serum levels
may still be highly relevant to schizophrenia therapy,
given the significant effects of glycine on positive and
depressive symptoms, particularly for patients who do
not respond to antipsychotics or are experiencing
adverse side effects of clozapine.
Consistent with its action as a partial agonist, an initial
dose-finding study with D-cycloserine added on to con-
ventional neuroleptics reported a U-shaped dose-
response curve with an intermediate dose that improved
negative as well as cognitive symptoms.
78 Given that the
GMS is not saturated in vivo, one might speculate that a
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receptor up to a point and then actually begin to com-
pete with the endogenous agonist. Furthermore, this
point of inflection in the nature of the D-cylcoserine
effect may vary depending on the individual patient’s
level of GMS saturation. D-cylcoserine may in any case
be an impractical approach for prolonged treatment, as
NMDA receptor desensitization has been observed with
chronic administration.
79The apparent lack of consistent
success of D-cycloserine use in schizophrenia stands in
contrast to the positive results observed with it in extinc-
tion therapy for specific phobias. The extinction of a con-
ditioned fear memory is an NMDA-dependent process,
80
which can be enhanced by positive modulation of the
GMS.
81,82 D-cycloserine has been effective in treating
acrophobia in combination of a virtual reality-based cog-
nitive behavioral therapy.
83,84 Thus, a key difference
between the successful application of D-cycloserine in
anxiety disorders and the unsuccessful application in
schizophrenia may be that the in the former it is used
acutely or subchronically as an adjunct to concomitant
activation of specific brain circuitry related to specific
fear or phobia.
D-serine itself is a potential therapy, as it has been
shown in rodents to be relatively efficient at crossing the
blood-brain barrier upon peripheral administration com-
pared to glycine,
85 and can persist in cortex thereafter.
86
In contrast to other GMS agonists, there is direct indi-
cation that D-serine is affected in schizophrenia, as it is
decreased in CSF
69 and serum from patients.
68 The sig-
nificant effects of D-serine on total psychopathology,
negative symptoms, and cognitive symptoms found in
the Tsai and Lin
74 meta-analysis are based only on small
trials that tested it as an add-on therapy to typical or
atypical antipsychotics. In the case of D-serine as well as
other agents, testing in conjunction with typical or atyp-
ical antipsychotics may occlude potential effects on pos-
itive symptoms, which are relatively well controlled with
available antipsychotics. Large Phase II trials of D-ser-
ine in schizophrenia and schizophrenia prodrome are
currently underway, both as an add-on to antipsychotics
and as a monotherapy.
An intriguing pattern in the literature on GMS agonists,
corroborated by the meta-analysis, is that they are inef-
fective when combined with clozapine as opposed to
other antipsychotics. These results together could be
explained by an effect of clozapine on GMS occupancy.
75
The mechanism of putative clozapine interaction with
NMDA receptors is not yet known, but increased
NMDA-mediated currents have been observed in the
presence of clozapine in rat frontal cortex,
87 and effects
on glycine transport have been proposed.
88 If clozapine,
which is superior to other atypical antipsychotics in treat-
ing negative and cognitive symptoms,
10 works through the
GMS, it may be possible to achieve comparable benefits
without the troubling side effects of clozapine such as
agranulocytosis, weight gain, and metabolic syndrome by
using other agents that enhance GMS occupancy.
D-amino acid oxidase
The peroxisomal enzyme D-amino acid oxidase (DAAO)
converts D-serine to hydroxy-pyruvate in the brain, yield-
ing hydrogen peroxide as a by-product.
89 DAAO expres-
sion was originally believed to be restricted to astrocytes
in the mammalian cerebellum,
90 but has since been
observed in neurons.
91 Inhibitors of DAAO would be
expected to increase D-serine in the brain, and could
thereby increase GMS occupancy. Direct evidence of
involvement of DAAO in schizophrenia is somewhat
controversial. DAAO has been implicated as a putative
schizophrenia gene by linkage and association methods,
but meta-analyses have revealed that the disease-associ-
ated variants of the gene are different across studies,
92,93
precluding a simple functional hypothesis based on the
findings. Postmortem studies of brain DAAO expression
in schizophrenia have reported elevated transcript levels
and enzyme activity.
69,94-96 G72, a mysterious putative
interacting protein of DAAO, is coded for in a linkage
region identified for schizophrenia by multiple studies,
and considered one of the strongest genetic risk factors
for schizophrenia identified using linkage analysis. The
link between G72 and DAAO originates from a yeast 2-
hybrid study from which DAAO emerged as a G72 inter-
actor.
97An in vitro functional assay suggested that G72
protein is an activator of DAAO; but more recent stud-
ies demonstrate that it inhibits DAAO. According to this
conceptualization, mutations in G72 would result in dis-
inhibition of DAAO, thereby reducing the availability of
D-serine. However, despite significant attention paid to
it pursuant to its repeated appearance in the schizophre-
nia genetic literature, to date the protein has been
observed only in heterologous expression systems. It
should be noted that DAAO activity is not specific to D-
serine, so manipulating the activity of this enzyme can
affect the levels of other D-amino acids.
Pharmacological aspects
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DAAO inhibitor programs. While there are no published
clinical data, preclinical studies have revealed promising
behavioral effects. Adage et al
98 reported that DAAO
inhibitor, AS057278, significantly increased cortical D-
serine, corrected PCP induced prepulse inhibition (PPI)
deficits and normalized PCP-induced hyperactivity, a
behavioral surrogate for psychosis. Hashimoto et al
99
found that combining D-serine with the DAAO
inhibitor, 5-chloro-benzo[d]isoxazol-3-ol (CBIO),
markedly increased cortical D-serine levels and cor-
rected dizocilpine-induced (MK801) PPI deficits.
However, another DAAO inhibitor, in spite of elevating
CSF D-serine levels, failed to normalize amphetamine-
induced hyperactivity and MK801-induced disruption of
cognition. As D-serine treatment was effective, it
appears that DAAO inhibition must be greater than
80%, the upper limit achieved by their drug.
100
D-Serine synthesis and transport
D-serine, the highest-affinity endogenous GMS agonist,
is synthesized from L-serine by the pyridoxal 5’-depen-
dent enzyme serine racemase. Polymorphisms in the 5’
untranslated region of the serine racemase gene, which
may be functionally related to levels of its promoter
activity, have been associated with schizophrenia.
101-103
Like DAAO, serine racemase was originally believed to
be restricted to astrocytes in its localization
104 but has
since been observed in neurons.
105,106 Genetic knockout
of serine racemase leads to a reduction of 80% to 90%
in brain D-serine in mice.
107The origin of the remaining
10% to 20% is unknown but may be diet and/or bacter-
ial flora. D-serine levels within the synapse are regulated
by the arginine-serine-cysteine transporter, ASC-1,
108
which is localized to neuronal somata and dendrites.
109,110
Inhibitors of ASC-1 have been proposed as therapeutics
in schizophrenia,
111 as they would presumably elevate
levels of extracellular brain D-serine. On a cautionary
note, constitutive ACS-1 gene deletion in mice has been
shown to cause tremors, seizures, and early postnatal
death.
112
GlyT1 inhibitors
The concentration of glycine in mammalian CSF is high
relative to its dissociation constant (Kd) for the GMS, but
local glycine levels are functionally regulated at the
synapse by the sodium-dependent glycine transporter-1
(GlyT1) expressed in astrocytes.
113,114 The activity of
GlyT1 is itself endogenously regulated by sarcosine (N-
methylglycine), an intermediate and byproduct in glycine
synthesis and degradation. Electrophysiological studies
in rodents suggest that inhibition of GlyT1 is more effec-
tive than exogenous application of glycine at potentiat-
ing NMDA receptor-mediated neurotransmission. For
example, in an acute hippocampal slice preparation,
NMDA receptor-mediated excitatory postsynaptic
potentitals (EPSPs) in CA1 hippocampal pyramidal neu-
rons were potentiated robustly by the sarcosine analog
N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]
sarcosine (NFPS), whereas perfusion with high concen-
trations of glycine (1 or 10 µM) had relatively little
effect.
67 Similar findings have been reported in acute
frontal cortical slices.
115 Systemic treatment with NFPS
increased NMDA receptor currents and LTP in the den-
tate gyrus and enhanced prepulse inhibition of the
acoustic startle response.
116
Sarcosine administered to patients in conjunction with
antipsychotics has shown some promise for treatment of
schizophrenia. A meta-analysis of clinical trials testing
the efficacy of GMS-enhancing agents found it effective
on total psychopathology, negative symptoms, and gen-
eral psychopathology.
74 However, undesirable side
effects of sarcosine-derived GlyT1 inhibitors have also
been noted, including ataxia, hypoactivity, and decreased
respiration, prompting the development of novel classes
of non-sarcosine-based inhibitors of GlyT1.
117 Several
GlyT1 inhibitors are in the early stages of clinical trials;
and Hoffman-LaRoche has reported that their GlyT1
inhibitor caused significant reductions in overall symp-
toms and especially negative symptoms in a Phase-II
clinical trial in schizophrenia.
Metabotropic glutamate receptors (mGluRs)
as therapeutic targets
Characteristics of mGluRs
While ionotropic glutamate (iGlu) receptors (AMPA,
kainate and NMDA subtypes) serve as the mediators of
excitatory (glutamatergic) signaling, G-protein coupled
metabotropic glutamate (mGlu) receptors act as modu-
lators of excitatory signaling. Given the increased inter-
est in the pathophysiological impact of dysfunctional
glutamate signaling and their role as modulatory recep-
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opment of therapeutics for schizophrenia and other psy-
chiatric disorders.
118-121 The mGluRs are members of
Class C of the G-protein coupled receptor superfamily.
Eight subtypes of mGluRs have been identified and
divided into three groups, based upon pharmacology,
sequence homology, and G protein coupling: Group I
(mGlu1 and mGlu5), Group II (mGluR2 and mGluR3),
and Group III (mGluR4, mGluR6, mGluR7, and
mGluR8) (for review, see ref 122). Each of these recep-
tors possesses a distinct expression pattern that relates
to physiological control over glutamatergic neurotrans-
mission at various levels including neurotransmitter
release, function of postsynaptic iGluRs, glial function,
and neuroplastic changes in postsynaptic neurons. These
discrete functions make these receptors very attractive
targets for pharmacological intervention. Group I and II
receptors have notably risen in interest as potential
treatments for schizophrenia because of their ability to
normalize dysfunctional glutamatergic neurotransmis-
sion thought to be a core feature of the disorder.
Group II mGluRs
Group II mGluRs are promising therapeutic targets
because of their role as autoreceptors in the regulation of
glutamate release from nerve terminals. Activation of
Gai/o-coupled mGlu2/3 receptors attenuate electrically
evoked excitatory neurotransmission.
123 Pharmacologically
evoked and spontaneous excitatory currents are attenu-
ated by mGluR2/3 activation, with effects predominantly
on the frequency of currents, supporting a presynpatic
mode of activity.
124,125 Preclinical observations have been
made that psychotomimetic drugs that act as noncompet-
itive blockers of NMDA receptors (eg, PCP, ketamine,
MK801) cause an increase in synaptic glutamate levels in
the prefrontal cortex (PFC).
126,127As reviewed above, the
deficient PV
+-GABAergic neuron function found in post-
mortem studies in schizophrenia has led to the hypothesis
that the pathophysiology of schizophrenia involves a dis-
inhibition of cortical glutamatergic neurons and that group
II mGluR-mediated reduction in glutamate release
account for their antipsychotic action.
128-130The develop-
ment of ligands selective for mGlu2/3 receptors has
allowed for the examination of this hypothesis in preclin-
ical models of schizophrenia. 
(1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-
4,6-dicarboxylic acid (LY379268) and (1S,2S,5R,6S)-
2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid)
LY354740 are highly selective agonists of mGlu2/3
receptors possessing >100-fold selectivity over other sub-
types of mGluRs.
131 These ligands have been shown to
reverse the behavioral disruptive effects of the psy-
chotomimetic PCP in numerous paradigms including
stereotypy and hyperactivity,
126,132-136 social interactions
and cognition.
137,138 These ligands also display apparent
antipsychotic efficacy by inhibiting the behavioral effects
of psychedelic hallucinogens that influence glutamater-
gic signaling via serotonin 2A receptors,
139 an effect
linked to the inhibition of glutamate release from nerve
terminals.
124 A structurally related compound, (-)-(1R,
4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-
dicarboxylic (LY404039), administered via a prodrug
form, exhibited promising efficacy in a Phase II clinical
trial, reversing positive and negative symptoms in schiz-
ophrenic patients as a standalone therapy.
140 This thera-
peutic efficacy was similar to that of olanzapine and was
achieved without any of the side effects of commonly
prescribed antipsychotics such as elevated prolactin,
weight gain, and extrapyramidal symptoms. The achieve-
ment of this clinical trial is twofold; it: (i) provides proof
of concept for the development and application of glu-
tamatergic based therapeutics and (ii) demonstrates the
predictive validity of the PCP/ketamine model of schiz-
ophrenia. This second point was initially supported by
research demonstrating that the cognitive-disruptive
effects of ketamine in humans were indeed attenuated
by an mGlu2/3 receptor agonist.
141
The work with mGluR2/3 receptor agonists also high-
lights another key mechanistic point about potential
schizophrenic therapies: they need not reverse hyper-
dopaminergic neurotransmission. All current therapies
block D2 receptors to some degree, which has been
assumed to be necessary for therapeutic efficacy. The
work of Moghaddam and Adams
127,138 illustrates that the
major element of psychotomimetic drug (PCP or keta-
mine) action is to stimulate glutamatergic neurotrans-
mission (paradoxical to the action of these drugs as
NMDA receptor blockers), with dopamine release coin-
cidental. Notably, mGluR2/3 agonists achieve behavioral
effects that are paralleled by inhibition of drug-induced
glutamate efflux without affecting drug-induced
increases in extracellular dopamine levels measured by
in vivo microdialysis.
126 Single-unit recordings in awake
rats are further illustrative; mGluR2/3 receptor agonists
reversed NDMA receptor blocker-induced disinhibition
Pharmacological aspects
368
PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:39  Page 368and dysregulation of prefrontal pyramidal neuron fir-
ing.
142 The results of these studies suggest that antipsy-
chotic efficacy can be achieved in the absence of a direct
effect on forebrain dopamine, an effect alluded to in ear-
lier research showing a temporal disconnect between the
behavioral effects of PCP and modulation of DA, but
not glutamate, brain levels.
126
Positive allosteric modulation of mGlu2 receptors
Efforts to refine the mGlu2/3 agonists have focused
upon finding a ligand that selectively activates mGlu2
receptors. Discriminating between mGluR2 and
mGluR3 subtypes has been difficult, as they share >90%
sequence homology. Expression studies suggest mGluR2
are predominately localized to presynaptic sites,
143 while
mGluR3 are localized more postsynaptically and in glial
cells.
144 Using mGluR2-deficient mice, the apparent
antipsychotic effects of mGluR2/3 agonists have been
attributed to mGluR2 activation.
145,146 These studies
demonstrate the potential for selective activiation of
mGluR2; however, efforts to develop agonists of the glu-
tamate-binding (orthosteric) site have not surprisingly
fallen short. Recently, greater efforts have been under-
taken to pursue ligands that activate the receptor
through sites other than agonist binding site, termed
allosteric sites. The success of these efforts illustrate that
while the orthosteric site is highly conserved between
the two receptors, allosteric sites are located in less con-
served regions of the receptor and can be selectively tar-
geted to modulate agonist-induced signaling.
147
Allosteric modulators can be either positive or negative
in direction of activity, causing an increase or decrease,
respectively, in the activity of orthosteric ligand induced
signaling by altering agonist affinity and/or efficacy of
G-protein coupling.
148 In the case of mGlu2 receptors,
efforts have been directed towards identifying positive
allosteric modulators (PAMs). To date, numerous PAMs
haven been identified and shown to possess selective
efficacy to enhance agonist activity at mGlu2 receptors
with dramatic selectivity over other targets.
135,149,150These
ligands increase the ability of endogenous glutamate and
exogenous agonists to reduce evoked excitatory postsy-
naptic potentials in brain slice preparations.
135,139,149,151
Behavioral studies show that mGlu2 receptor PAMs
possess efficacy similar to that of mGluR2/3 agonists,
reducing PCP induced locomotion,
134,135 decreasing fear-
potentiated startle
150,151 and diminishing hallucinogen-
induced stereotypies.
139 Interestingly, one study showed
that one PAM, biphenyl-idanone A (BINA), was capa-
ble of uniquely reducing PCP-induced deficits in PPI.
These studies demonstrate the validity and therapeutic
potential of selectively targeting mGluR2. While issues
of in vivo potency remain for currently available ligands,
PAMs possess potential benefits. The selective potenti-
ation of endogenous signaling would work to enhance
the activity-dependent neurotransmission, while avoid-
ing the potentially deleterious effects of persistent recep-
tor activation, notably desensitization and tolerance.
135
Cystine-glutamate exchanger
Discussion of mGluR2 activation has focused on the
development of ligands that directly target these recep-
tors with either direct agonists or PAMs that require
endogenous glutamate for activity. An additional way to
enhance activity at these receptors is through the mod-
ulation of extrasynaptic glutamate levels. The cystine-
glutamate exchanger maintains 60% of the extra-synap-
tic glutamate concentration.
152 The exchanger is located
on the glial cell membrane and releases glutamate in a
1:1 ratio with the import of cystine.
153 Activation of this
exchanger produces a reduction in excitatory neuro-
transmission by mGluR2/3-dependent mechanism.
154The
compound N-acetylcysteine (NAC) is a substrate for this
exchanger that substitutes for cystine. The work of
Kalivas and colleagues has done much to demonstrate
the behavioral effects of NAC in a preclinical model of
drug-seeking behavior used to understand addiction. In
these studies, NAC reduces drug-seeking behaviors and
reinstatement of drug consumption after extinction
152,155
in a manner that is similar to the effects of an mGluR2/3
agonist.
156 More germane to the current review, recent
work has demonstrated the ability of NAC to reverse
PCP-induced deficits in cognition and social interactions,
as well as PCP-induced activation of glutamate release
in the prefrontal cortex of rodents.
157
These findings provide an additional context for the
interpretation of results of a recent clinical trial with
NAC (or placebo control) given as an adjunct therapy to
schizophrenic patients.
158 The investigators saw a signif-
icant improvement over placebo in Positive and
Negative Symptom Scale (PANSS) negative scale and
overall Clinical Global Impression (CGI-S) after 24
weeks of treatment. General functioning (Scale of
Global Assessment of Functioning) improved within a
Novel therapeutic targets in schizophrenia - Coyle et al Dialogues in Clinical Neuroscience - Vol 12 . No. 3 . 2010
369
PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:39  Page 369comparison of NAC-treated patients, but not as a com-
parison to placebo treatment (NB, within-group com-
parison of placebo treatment was not significant). The
investigators undertook this clinical trial to test the effect
of restoring glutathione deficiency in schizophrenia as a
treatment. Cystine and correspondingly NAC are pre-
cursors to the production of glutathione, a molecule nec-
essary for the protection against the effects of reactive
oxygen species.
153 Is the physiological effect of NAC
treatment prevention of oxidative damage or a restora-
tion of glutamatergic tone on presynaptic mGluR2/3? In
spite of preclinical studies demonstrating that mGluR2/3
antagonists block the effects of NAC, further studies
need to be done to clarify this point. Perhaps the bene-
ficial effects of NAC are twofold at the molecular level.
Given the sensitivity of NMDA receptor function to
redox state,
159,160 this might be an ideal way to use a sin-
gle therapy to target NMDA receptor hypofunction and
oxidative stress.
Activation of mGlu5 receptors
While development of ligands targeting group II mGluRs
is focused on reversing excessive, dysfunctional glutamate
release downstream of cortical disinhibition, mGluR5
selective activators are sought to directly reverse NMDA
receptor hypofunction though enhancement of the
ionotropic receptor activity. A functional link is formed
between Gaq-coupled postsynaptic mGlu5 receptors and
NMDA receptors by the scaffolding protein Homer and
Shank interacting with the postsynaptic density.
161
NMDA receptor signaling in hippocampal slices is selec-
tively potentiated by the mGlu5 agonist (RS)-2-Chloro-
5-hydroxyphenylglycine (CHPG).
162,163The specificity for
mGluR5 versus mGluR1, of this effect on NMDA recep-
tor currents is further demonstrated by the absence of
potentiated signaling in the presence of mGluR5 (but not
mGluR1) antagonists.
163,164
Available mGluR5 agonists suffer from poor brain pen-
etration. As a result, much of the in vivo preclinical
work demonstrating the role of mGlu5 receptors was
done using the centrally active mGluR5-selective antag-
onist 2-Methyl-6-(phenylethynyl)pyridine hydrochlo-
ride (MPEP). MPEP potentiates the locomotor hyper-
activity
165-167 and PPI disruption
165-167 caused by either
PCP or MK801. These effects were seen without any
effect on activity or PPI in the absence of PCP/MK801.
MPEP also enhances the detrimental effects of PCP/
MK801 in cognitive tasks of working memory and
instrumental learning.
167,168 In vivo single-unit recordings
show that MPEP enhances the MK801-induced increase
in neuronal activity, thereby linking the behavioral find-
ings back to the electrophysiology.
169
Like the Group II mGluRs, recent research demonstrates
that the most effective strategy to selectively activate
mGlu5 versus mGlu1 may be through the use of 
PAMs. Two unique PAMs, 3-Cyano-N-(1,3-diphenyl-
1H-pyrazol-5-yl)benzamide (CDPPB) and (S)-(4-
fluorophenyl)-(3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-
5-yl]piperidin-1-yl)methanone (ADX47273), have been
developed and shown to display dramatic mGluR5-selec-
tivity and the ability to increase the efficacy of glutamate
to activate mGlu5-mediated potentiation of NMDA
receptor signaling.
166,170 Furthermore, the PAMs are sys-
temically active and display antipsychotic-like properties,
blocking amphetamine-induced hyperactivity,
166,170,171 PCP-
induced hyperactivity,
170 and amphetamine/apomorphine-
induced disruption of PPI.
166,171 In the 5-choice serial reac-
tion time task, ADX47273 reduced impulsive errors.
170
Taken together these results demonstrate the potential
antipsychotic-like ability of mGlu5 receptor PAMs to
reduce the behavioral effects of multiple classes of psy-
chotomimetics as well as produce procognitive effects.
The efficacy in models of disrupted PPI is a divergence
from that of mGluR2/3 agonists and suggests that these
two approaches might have distinct therapeutic profiles.
The limited preclinical testing and absence of any clini-
cal demonstration of mGluR5 activation as a therapeu-
tic target in schizophrenia temper enthusiasm. However,
the demonstrated ability to enhance NMDA receptor sig-
naling at the neuronal level will encourage the future
development and testing of mGluR5 ligands.
GABAA receptors as therapeutic targets for
schizophrenia
GABAergic pathology in schizophrenia
There is now substantial evidence that GABA signaling
is deficient in corticolimbic regions, particularly in the
dorsal lateral prefrontal cortex (DLPFC) and hip-
pocampus, of patients with schizophrenia. One of the
most consistent postmortem findings in schizophrenia is
a reduction in the mRNA expression level of GAD67 in
PV
+-GABAergic interneurons, as well as reductions in
PV expression itself.
172 PV
+ interneurons exhibit fast-
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region of pyramidal neuron axons, and are therefore
thought to play a key role in controlling the overall fir-
ing properties of brain networks. Recent pharmacologi-
cal, immunological, and genetic evidence from animal
models suggests that inflammatory cytokine exposure
(increased oxidative stress) and NMDA receptor hypo-
function occurring during cortical development leads to
permanent disturbances in neuronal circuits, specifically
in the population of PV-containing interneurons.
173
The reduced GABA signaling by PV
+-interneurons onto
pyramidal neurons could contribute to the working
memory deficits observed in schizophrenia. PV
+-
interneurons control the rate of pyramidal cell firing,
thereby synchronizing oscillatory activity of cortical
pyramidal neurons in the gamma band range (30 to 80
Hz).
174 Gamma oscillations regulate working memory
and the transmission of information between cortical
regions. Therefore, it is hypothesized that the asynchro-
nous pyramidal neuronal activity resulting from aber-
rant PV
+ GABAergic signaling contributes to the cog-
nitive dysfunction observed in schizophrenia. It is
because of this hypothesis that GABAA receptors are
now being considered a viable pharmacologic target for
treating the cognitive disturbances associated with schiz-
ophrenia.
172
GABAA receptors are membrane proteins that form a
heteropentameric GABA-gated chloride channel, which
mediate largely tonic and phasic inhibition. They are
composed of several classes of subunits (α1-6, β1-3, γ1-
3, δ, ε, θ, π, ρ1-3), but generally consist of three types of
subunits (α, β, γ). The majority of GABAA receptors are
characterized by their sensitivity to benzodiazepines.
These receptors contain   subunits (α1, α2, α3, or α5), a
β  subunit (mainly β2 or β3), and in almost all cases the
γ2 subunit in a 2:2:1 stoichiometry. Benzodiazepine-
insensitive receptors contain α4, α6, or δ instead of γ2. In
addition to their structural diversity, GABAA receptor
subtypes have different expression patterns, pointing to
unique roles for these receptor subtypes in regulating
neuronal activity.
175
Postmortem and genetic evidence suggest that α2/α3-
containing GABAA receptors are the most relevant tar-
gets for the treatment of cognitive dysfunction in schiz-
ophrenia. It is the α2-containing GABAA receptors that
are up regulated on the postsynaptic axon initial seg-
ments of pyramidal neurons in schizophrenia.
176 In mice,
deletion of the α3 subunit results in mild hyperactivity
and a pronounced deficit in PPI of the acoustic startle
response, suggesting a hyperdopaminergic phenotype.
177
Targeting these specific receptor subtypes would cir-
cumvent the adverse cognitive and sedative effects asso-
ciated with nonspecific agonists, like benzodiazepines,
which are attributable to their affinity for α1 and/or α5-
containing GABAA receptors.
178
α2-GABAA receptors
A recent proof-of-concept trial was conducted with MK-
0777, a benzodiazepine-like compound selective for
GABAA receptors containing α2 or α3 subunits, to deter-
mine whether selective enhancement of GABAergic
transmission would improve cognitive functions and
gamma oscillations in patients with schizophrenia.
179 MK-
0777 improved the performance of patients in several
working memory tasks, and was associated with increased
gamma band power in the frontal cortex during task per-
formance. However, MK-0777 did not significantly alter
scores on the Brief Psychiatric Rating Scale (BPRS) or
Repeatable Battery for the Assessment of
Neuropsychological status, except for improvement in the
delayed memory index in the latter test. 
α3-GABAA receptors
Mouse genetics supports the hypothesis that α3-
GABAA receptors are involved in sensorimotor gat-
ing,
177 a process that is disrupted in schizophrenia.
Compounds that would selectively augment signaling
through these receptors would be potentially beneficial
in treating this schizophrenia endophenotype. As the α3-
containing GABAA receptor is the major subtype
expressed on dopaminergic and other monoaminergic
neurons,
180 agonists at this receptor might augment the
inhibitory tone of these neurons and reverse their hyper-
functioning state in psychosis. 
Cholinergic therapeutic targets
Muscarinic receptors
Muscarinic acetylcholine (mACh) receptors are widely
distributed throughout the neocortex and are promising
targets for numerous neurological and psychiatric dis-
orders.
181 Five isoforms (M1-M5) of these G-protein cou-
pled metabotropic receptors have been identified and
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182The therapeutic potential for muscarinic
receptor activation in schizophrenia is fueled in large
part by the efficacy of acetylcholine esterase inhibitors,
which elevate synaptic acetylcholine levels, in reducing
behavioral disturbances in Alzheimer’s disease patients
that are reminiscent of symptoms of schizophrenia.
183,184
These effects are in addition to the primary cognitive
enhancement due to the therapy. Efficacy of these treat-
ments could likely be due to downstream activation of
mACh receptors. Consistent with the hypothesized ther-
apeutic impact of mACh receptor activation is a small
clinical trial in schizophrenia showing antipsychotic effi-
cacy of the putative M1/M4 selective mACh receptor
agonist xanomaline.
185
Current cholinergic therapeutics are limited in their
applicability because of aversive side-effect profiles that
are attributed to peripheral activation of M2 and M3
mACh receptors.
186,187 For this reason, the development of
subtype selective ligands has been a major interest. M1
and M4 subtypes are of greatest interest in schizophre-
nia, given the efficacy of xanomaline (an M1/M4-prefer-
ring agonist) and postmortem findings of reduced M1
and M4 receptor densities in schizophrenia.
188,189 Studies
with mutant mice support the targeting of M1 and M4
receptors. Null deletion mutants of M1 receptors display
deficits in working memory and social memory,
190 as well
as elevated baseline dopamine turnover and increased
sensitivity to the behavioral and neurochemical effects of
amphetamine.
191 Likewise M4 null mutant mice display
hypersensitivity to amphetamine and PCP-induced
increases in nucleus acccumbens dopamine, consistent
with an involvement of NMDA receptors.
192
In the absence of selective pharmacological tools,
mutant animal studies have been used to improve our
understanding of the neurophysiological role of mACh
receptors.
187 M4 null mutant mice display enhanced base-
line ACh efflux with in vivo dialysis in various brain
regions, consistent with a prominent role as an autore-
ceptor
193 The finding that M1 null mutation abolishes
ACh-mediated LTP of pyramidal neurons in the hip-
pocampus
194 complements earlier work suggesting a sim-
ilar role for M1 receptors in the potentiation of NMDA
receptor currents.
195 Taken together, these studies sug-
gest that M1 mACh receptors possess activity similar to
that of mGlu5 receptors, modulating NMDA receptor
signaling postsynaptically. 
mACh receptors, like mGluRs, have proven to be difficult
to selectively target at the orthosteric site. The agonist
xanomaline, though often touted as M1/M4-selective, pos-
sesses prominent affinity for other subtypes. Recent
progress has been made in the development of M1 and M4
PAMs and allosteric agonists for mACh receptors.
196As
with mGlu receptors, allosteric modulation appears to be
a promising route for achieving pharmacological selectiv-
ity. Recent studies describe the activity of a M1-selective
allosteric agonist, 1-(1'-2-methylbenzyl)-1,4'-bipiperidin-
4-yl)-1H-benzo[d]imidazol-2(3H)-one (TBPB) and a
PAM, benzylquinolone carboxylic acid (BQCA). In exper-
iments that further elucidate the physiological roles of M1
receptors, TBPB enhances NMDA receptor currents;
BQCA enhances the frequency and amplitude of sponta-
neous excitatory neurotransmission in the cortex.
197 In evi-
dence of in vivo activity, TBPB reduced amphetamine-
induced hyperactivity
198 and BQCA enhanced reversal
learning in a murine transgenic model of Alzheimers’ dis-
ease.
199 Likewise, the selective targeting of M4 receptors
has proven successful via allosteric modulation.
197,200,201
These PAMs display in vivo efficacy, reducing ampheta-
mine-induced hyperactivity (VU0152099201; and apo-
morphine-induced disruption of PPI (LY2033298).
200These
limited pharmacological studies serve as merely a proof of
concept. As these compounds (and others with optimized
pharmacokinetics) are more widely tested, we are likely to
gain a better understanding of the function of and thera-
peutic potential for targeting M1 and M4 ACh receptors.
Nicotine and schizophrenia
The involvement of nicotinic acetylcholine receptors
(nAChRs) in the pathophysiology of schizophrenia was
initially suggested by behavioral and biochemical data.
People with schizophrenia, in both inpatient and out-
patient settings, smoke cigarettes at a rate (80%) more
than threefold higher than the general population
smoking rate in the United States.
202 They are also
heavier smokers
203 and extract more nicotine per ciga-
rette smoked than the general population.
204 Their
motivation to quit smoking is low
205 and the smoking
cessation rates are lower than the rates of the general
population.
203 Furthermore, in schizophrenic patients,
cigarette smoking normalized their deficits in sensory
gating.
206 Patients with schizophrenia also have reduc-
tions in the numbers of [
3H]-cytisine and [
125I]-a-
bungarotoxin binding sites in the hippocampus as well
as elevated serum levels of nAChR antibodies com-
pared with controls.
207
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phrenic subjects suggest that they might be medicating
themselves with nicotine to reduce cognitive impair-
ments associated with the disorder and/or antipsychotic
treatment. Patients report that they smoke as a sedative,
to reduce negative symptoms, and to counteract med-
ication side effects.
208 Studies have demonstrated that
nicotine administration produces positive effects on sen-
sory gating, eye movements, negative symptoms, some
cognitive tasks, and movement disorders. Although nico-
tine is therapeutic for certain aspects of schizophrenia,
it has several limitations that hinder its clinical utility.
Nicotine induces tachyphylaxis and carries abuse liabil-
ity. The long-term risks of chronic treatment are
unknown but might include carcinogenic features and
cerebro- or cardiovascular risks. Therefore, novel nico-
tinic agonists have been developed that are more selec-
tive than nicotine for particular nAChR subtypes, and
may provide cognitive benefits similar to nicotine, with
fewer adverse side effects. 
nAChRs
Neuronal nAChRs are widely expressed in the central
nervous system and mediate fast synaptic signaling and
the release of other neurotransmitters. They are involved
in numerous physiological functions including cognition
(attention and working/associative memory perfor-
mance), neuronal development, particularly in the sen-
sory cortex, and reward mechanisms via the mesocorti-
colimbic system.
209 Cholinergic modulation also plays a
critical role in the functioning of neural circuits, includ-
ing those involving glutamatergic, GABAergic, and
dopaminergic innervations. 
nAChRs are excitatory neurotransmitter-gated ion chan-
nels that belong to a superfamily that includes other
ionotropic receptors for 5-HT, glycine, and GABA. This
family of receptors is comprised of 16 different subunits
in humans (α1-7, α9-10, β1-4, δ, ε, γ). This wide variety
of subtypes of nAChRs arising from combinations of
subunits displays a range of different functional and
pharmacological properties. Neuronal nAChRs are
assembled from five transmembrane subunits that are
arranged around a central water-filled pore. Neuronal
subunits that form nAChRs in αβ combinations include
α2–α6 and β2–β4. Although most nAChRs subunits
assemble only into heteropentameric receptor ion chan-
nel combinations, the α7 subunits are able to generate
functional homomeric nAChRs.
209 nAChRs composed of
α4β2 and α7 subunits make up the majority of the
nAChRs in the brain. There are two ACh binding sites
per receptor. Mammalian nAChRs are cation-selective,
being permeable to small monovalent and divalent
cations like Ca
2+. Nicotinic receptor activity causes depo-
larization, and the divalent cation permeability plays an
important physiological role by supplying ionic signals,
including Ca
2+.
α7nAChRs
α7 nAChRs are abundantly expressed in the hippocam-
pus and cortex. They have distinct characteristics due to
their homopentameric composition that distinguishes
them from the other nAChR subtypes. α7 nAChRs are
rapidly desensitizing, are an order of magnitude less sen-
sitive to nicotine as an agonist, and have a higher cal-
cium permeability than other nAChRs.
209
Because cholinergic innervation arises from projections
that send diffuse afferents to a broad range of brain
areas, nicotinic activity is a modulatory signal that sub-
tly influences many neurotransmitter systems and con-
tributes to the overall efficiency of various neural 
circuits. Cholinergic fibers innervate the entire hip-
pocampus with synaptic contacts made onto granule
cells, pyramidal cells, interneurons, and neurons of the
hilus.
210 The hippocampus expresses a wide variety of
nAChR subunits, but the α7, α4, and β2 subunits pre-
dominate. The GABAergic interneurons more densely
express nAChRs than do the glutamatergic cells.
Activation of α7nAChRs on presynaptic terminals of
glutamatergic pyramidal neurons increases intratermi-
nal Ca
2+ levels to facilitate glutamate release.
211
α7nAChRs are also present in high density at postsy-
naptic sites on PV
+-GABAergic interneurons
212 that are
vulnerable in schizophrenia,
130 where they mediate fast
cholinergic excitatory transmission.
213 In the cortex,
cholinergic innervation sparsely reaches all layers, but
layer V is the most heavily innervated, especially in the
motor and sensory areas. The manner in which nicotinic
signaling affects cortical activity is dependent on which
part of the pyramidal cell the nAChRs are activated.
Activation of nAChRs on distal apical dendrites depo-
larizes the cell and promotes action potential firing,
while activation on proximal apical dendrites reduces
membrane impedance and shunts signals from the api-
cal tuft.
209 Midbrain dopamine neurons in the substan-
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variety of nAChR subunits (α4-α7 and β2), with β2 sub-
unit containing nAChRs dominating (~40% of rat
dopaminergic VTA neurons express the a7nAChR sub-
unit.
214 Cholinergic afferents into the midbrain enhance
glutamate transmission via mainly presynaptic α7
nAChRs on glutamatergic terminals,
215 thereby influ-
encing the firing frequency and firing modes of DA neu-
rons.
216
Association of α7nAChRs with schizophrenia
α7 nAChRs have been associated with schizophrenia
across several domains. A linkage was found between
the  α7 nAChR and schizophrenia on chromosome
15q13-14,
206 a region containing the gene that encodes
for the α7 nAChR (CHRNA-7). Although no amino
acid-coding region polymorphisms have been found,
multiple single-nucleotide polymorphisms (SNPs) in the
promoter region of CHRNA-7 as well as a partial dupli-
cation of CHRNA-7, have been characterized, with cer-
tain alleles more frequently present in people with schiz-
ophrenia.
217 Reduced α7 receptor binding was found in
the reticular nucleus of the thalamus,
218 hippocampus,
219
and cingulate cortex.
220 Moreover, there were reduced
α7 subunit levels in the DLPFC,
221 as well as reduced
mRNA expression of α7 in peripheral blood lympho-
cytes
222 of patients with schizophrenia. In addition to the
clinical data, preclinical evidence implicates α7nAChR
function in regulating cognition. Mice deficient in
α7nAChRs have impaired sustained attention,
223 while
administration of α7nAChR antagonists
224 and agonists
225
impair and enhance, respectively, working memory in
rodents.
α7nAChR full agonists
The α7nAChR agonist, (-)-spiro[1-azabucyclo[2,2,2]octane-
3,5’-oxazolidin-2’-one] (ARR 17779), significantly
improved learning and memory in rats,
225 while an
α7nAChR agonist with 5-HT3 receptor antagonist proper-
ties, improved the inhibition of the P50 response in schizo-
phrenia.
226 A novel selective α7nAChR agonist, 5-mor-
pholin-4-yl-pentaoic acid (4-pyridin-3-yl-phenyl)-amide
(SEN12333), with only weak antagonist activity at α3-con-
taining receptors, was shown to have procognitive proper-
ties in rats across several domains, including episodic mem-
ory, attention, and perceptual processing.
227
α7nAChR partial agonists
3-(2,4 Dimethoxy)benzylidene-anabaseine (DMXBA)
is one of a series of compounds derived from anabaseine,
an alkaloid found in marine worms. DMXBA is a partial
agonist at the α7nAChR and is a weak competitive
antagonist at the α4/β2 nAChR and at the 5-HT3 recep-
tor. The metabolites of DMXBA are also active at these
receptors, but their biological effect may be limited due
to their greater polarity, and therefore greater difficulty
in crossing the blood-brain barrier. In preclinical animal
models, DMXBA was shown to improve learning and
memory-related behaviors in multiple paradigms, includ-
ing nonspatial avoidance task,
228 delayed matching to
sample,
229 Morris water maze,
228 and classic eye-blink
conditioning.
230 DMXBA also normalizes auditory gat-
ing in the DBA/2 mouse, a strain with no sensory inhi-
bition under routine experimental conditions.
231
Because of the success of DMXBA in preclinical trials,
its effects on cognition were initially evaluated in nor-
mal subjects.
232 DMXBA significantly improved simple
reaction time, correct detection during digit vigilance,
both immediate and delayed word recall, word and pic-
ture recognition memory, and performance speed on a
numeric and spatial working memory task.
233 A second
Phase I trial was conducted in persons with schizophre-
nia.
234This double-blind study found that DMXBA nor-
malized auditory evoked responses in both the P50 ratio
and the test wave amplitude in patients. DMXBA also
improved performance on the Repeatable Battery for
the Assessment of Neuropsychological Status (RBANS)
and the Attention subscale, with effect sizes more favor-
able when compared with second-generation antipsy-
chotics. However, DMXBA did not produce changes in
the BPRS and therefore did not affect positive, negative,
or anxiety related symptoms. 
An initial Phase II trial recently assessed the clinical
effects of DMXBA on the Measurement and Treatment
Research to Improve Cognition in Schizophrenia
(MATRICS) Consensus Cognitive Battery, as well as the
Scale for the Assessment of Negative Symptoms (SANS)
and Brief Psychiatric Rating Scale (BPRS).
235Although
DMXBA did not significantly improve MATRICS cog-
nitive measures, patients reported significant improve-
ments on the SANS total score, most notably on the anhe-
donia and alogia subscales. fMRI was also conducted in
this trial to ascertain if DMXBA would have an effect on
hippocampal activity.
236 In schizophrenia, increased hip-
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many tasks, including smooth pursuit eye movements, and
is thought to be the result of hippocampal interneuron
dysfunction. DMXBA (150 mg) reduced hippocampal
activity in patients during pursuit eye movements consis-
tent with the established function of α7nAChRs on hip-
pocampal inhibitory interneurons. 
R3487/MEM3454 is a partial α7nAChR agonist and a 5-
HT3 receptor antagonist. R3487/MEM3454 has been
shown to be efficacious in multiple animal behavioral
paradigms that evaluate episodic, spatial, and working
memory function as well as sustained attention.
237 4-bro-
mophenyl-1,4-diazabicyclo[3,2,2]nonane-4-carboxylate-
hydrochloride (SSR180711) is a partial a7 nAChR ago-
nist, with no significant binding and/or functional activity
at other human nAChRs. This compound produced elec-
trophysiological, biochemical, and behavioral effects pre-
dictive of cognitive benefit in schizophrenia.
238,239
SSR180711 also normalized abnormally persistent latent
inhibition produced by an acute pharmacologic model
(MK801) and a neurodevelopmental model (inhibition
of nitric oxide production during the very early postna-
tal period), which are used as models of impaired cogni-
tive flexibility in schizophrenia.
240 Moreover, SSR180711
reversed amphetamine-induced disruption of latent inhi-
bition, an effect considered to be predictive of activity
against the positive symptoms of schizophrenia.
240
Positive allosteric modulators of α7nAChRs
Positive allosteric modulators of α7nAChRs have
attracted interest as potential compounds for the treat-
ment of cognitive deficits associated with schizophrenia.
α7nAChRs PAMs have been classified as either type I or
type II compounds. Type I compounds mainly affect the
peak current response, while type II compounds affect
both the peak current response, as well as the kinetics of
agonist-evoked responses.
241 1-(5-chloro-2, 4-dimethoxy-
phenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-120956)
is a prototypical type II PAM with little or no activity on
most other nAChR subtypes.
242 LY-2087101 is a recently
discovered allosteric potentiator of nAChRs that is less
selective for α7 nAChRs than PNU-120956, with prop-
erties similar to type I PAMs.
243 There are five amino
acids in three a-helical transmembrane regions of the
α7nAChR that are critical in facilitating the potentiaton
of agonist evoked responses by PNU-120956 and LY-
2087101.
244 In addition to amplifying or unmasking
α7nAChR responses to exogenous agonist, PAMs can
potentially augment the effects of endogenous agonist,
especially PNU-120956, since it reduces α7nAChR
desensitization.
242
Genetic, biochemical, and behavioral findings have
linked α7nAChRs to schizophrenia, particularly the cog-
nitive and sensory processing components of the dis-
ease.
245 The ability of α7nAChR agonists (partial and
full) and PAMs to improve a wide range of cognitive
processes preclinically, and to a lesser extent clinically,
makes them attractive targets for mitigating the cogni-
tive deficits associated with schizophrenia that are not
responsive to current first- and second-generation
antipsychotics.
Conclusion
While this review is hardly exhaustive, it does identify a
number of potential drug discovery targets that could
address the symptoms most resistant to current treat-
ments available for schizophrenia. As psychosis is a
downstream consequence of a primary cortical dysfunc-
tion, it is possible that some of these interventions might
not only affect the cognitive deficits and negative symp-
toms, but also positive symptoms. In this regard, the
mGluR2/3 agonist, LY2140023, which has no direct
effects on dopaminergic neuronal function, exhibited
antipsychotic effects comparable to the positive control,
olanzapine.
140 Alternatively, other interventions might
have only selective effects on negative symptoms and/or
cognition, and thus would require the coadministration
of an antipsychotic to reduce positive symptoms, much
in the way that the combination of a mood stabilizer and
an antipsychotic are used to treat bipolar disorder. 
As the complex genetics of schizophrenia are resolved, it
may be possible in the future to link risk genes to drugs
that directly address their mechanisms. For example, an
α7nAChR positive modulator might be particularly effec-
tive in those patients found to have an allelic variant of
the CHRNA7 promoter that is associated with reduced
expression.
246 Genetic studies indicate that individual risk
genes such as common alleles of GABAA receptors are
associated with elevated risk for schizophrenia, bipolar
disorder, and autism-spectrum disorders.
247 Such shared
risk genes or shared copy number variants provide face
validity for the conviction that drug discovery around
these targets may yield a much broader therapeutic
impact than just in schizophrenia. However, in keeping
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drugs targeting these pathways will likely be useful only
in particular subgroups of patients with schizophrenia,
bipolar disorder, and autism-spectrum disorders. ❏
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Más allá del receptor de dopamina: 
nuevos blancos terapéuticos para tratar la
esquizofrenia
Todos los fármacos actuales aprobados para tratar
la esquizofrenia parecen ejercer sus efectos anti
psicóticos a través del bloqueo del receptor de
dopamina D2. Recientes estudios de meta-análisis y
de eficacia comparativa muestran diferencias meno-
res entre la eficacia de los antipsicóticos atípicos
más nuevos y los más antiguos, y escasos efectos
sobre los síntomas negativos y cognitivos. Esta revi-
sión integra los hallazgos de estudios postmortem,
de imágenes y de pruebas con fármacos para acla-
rar un “circuito patológico” córtico-límbico en la
esquizofrenia que pueda ser de particular impor-
tancia para los síntomas negativos y los deterioros
cognitivos de la esquizofrenia. Se discuten los
potenciales sitios para la intervención farmacoló-
gica de blancos en la neurotransmisión glutama-
térgica, gabaérgica y colinérgica para tratar estos
síntomas de la esquizofrenia.  
Au-delà du récepteur dopaminergique : 
de nouvelles cibles thérapeutiques pour 
traiter la schizophrénie.
Tous les médicaments actuels autorisés dans le trai-
tement de la schizophrénie exercent leur action
antipsychotique en bloquant le récepteur D2 à la
dopamine. Selon des métaanalyses récentes et des
études d’efficacité comparatives, les différences d’ef-
ficacité entre les antipsychotiques atypiques les plus
récents et les médicaments les plus anciens sont mar-
ginales et les effets sur les symptômes négatifs et
cognitifs sont faibles. Cet article présente les résul-
tats d’études d’imagerie, d’études postmortem, et
de tests de compétition pharmacologique afin de
trouver un « circuit pathologique » corticolimbique
dans la schizophrénie, qui serait particulièrement
pertinent pour les symptômes négatifs et les déficits
cognitifs dans cette maladie. Les sites potentiels de
l’action pharmacologique visant la neurotransmis-
sion glutamatergique, GABAergique et choliner-
gique pour traiter ces symptômes sont analysés.
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